Here's Why Agios Pharmaceuticals Stock Soared Today (Hint: It's FDA-Related)

Agios Pharmaceuticals stock surged over 14% after the FDA accepted its supplemental New Drug Application for mitapivat for sickle cell disease with Priority Review status and set a decision goal date of November 1. While the drug failed to meet its primary endpoint for reducing sickle cell pain crises, the FDA's accelerated approval pathway indicates confidence in the submitted data. Full traditional approval remains contingent on a confirmatory Phase 3 trial expected next year.